Alpha-blocker therapy does not decrease the risk for prostate cancer death, but it is associated with an elevated risk for low-grade prostate cancer. Preclinical studies have suggested that ...
Novel N-of-1 study design showed minimal treatment effect for 11 of 30 patients ...